Novartis slipped this news out late yesterday. It has received approval for Voltaren Gel (diclofenac) in pain associated with osteoarthritis (see press release ). Diclofenac has been on the market for…forever, so the benefit to the company is likely to be slight.
Voltaren’s indication isn’t going to make up the distance for Prexige being MIA.
Voltaren’s indication isn’t going to make up the distance for Prexige being MIA.